P662: Remission to vedolizumab is not higher in TNF-naïve compared with TNF-pre-treated patients with Crohn’s disease
ECCO '19 Copenhagen
2019
P663: The effect of vitamin D deficiency, and its correction, on healthcare utilisation among patients with inflammatory bowel disease (IBD)
ECCO '19 Copenhagen
2019
P664: SB5 and reference adalimumab show cross-immunogenicity in patients with inflammatory bowel disease or rheumatoid arthritis
ECCO '19 Copenhagen
2019
P665: 1-Year clinical and endoscopic follow-up of vedolizumab therapy in refractory PIBD patients
ECCO '19 Copenhagen
2019
P666: Safety of combination biologic and immunosuppressive therapy post-orthotopic liver transplantation in patients with inflammatory bowel disease: a systematic review
ECCO '19 Copenhagen
2019
P667: Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates in 72 patients, a report from a district general hospital
ECCO '19 Copenhagen
2019
P668: Ustekinumab induction effectiveness in Crohn’s disease in a real-life cohort
ECCO '19 Copenhagen
2019
P669: Transmural healing is associated with higher infliximab trough levels in Crohn’s disease
ECCO '19 Copenhagen
2019
P670: Therapeutic efficacy and economic impact of half sulfasalazine therapy for refractory ulcerative colitis
ECCO '19 Copenhagen
2019
P671: Experiences of using vedolizumab in the treatment of inflammatory bowel disease in the East Midlands: a retrospective observational study
ECCO '19 Copenhagen
2019
P672: Drug therapy and monitoring for inflammatory bowel diseases: preliminary data from a multi-centre investigation in Asia
ECCO '19 Copenhagen
2019
P673: Achievement of tight control based on serum C-reactive protein and albumin correlated with better outcomes in Japanese Crohn’s disease patients treated with biologics
ECCO '19 Copenhagen
2019
P674: Blood thiopurine level, anti-TNF drug level and body composition parameters in inflammatory bowel diseases patients: a cross-sectional study in a Hungarian IBD centre
ECCO '19 Copenhagen
2019
P675: The relationship between gender, severity of disease, treatment type, and employment outcome in patients with inflammatory bowel disease in Israel
ECCO '19 Copenhagen
2019
P676: The impact to disease activity, iron and vitamin D deficiency on fatigue in IBD patients
ECCO '19 Copenhagen
2019
P677: Effect of late faecal loss of infliximab on treatment response of inflammatory bowel disease
ECCO '19 Copenhagen
2019
P679: Development of a novel auto-injector of subcutaneous CT-P13 infliximab: Phase I randomised, open-label, single-dose trial to compare the pharmacokinetics and safety to pre-filled syringe in healthy subjects
ECCO '19 Copenhagen
2019